Updates in Retinal Disease Care: Keeping an Eye on Emerging Anti-VEGF Therapies & Improved Outcomes
Credit(s): 1.00 (60 min)
Release Date: Dec 20, 2022
Expiration Date: Dec 20, 2023
Physicians – AMA PRA Category 1 Credit(s) ™
Physicians/ABO MOC – ABO MOC Point(s)
The prevalence of retinal diseases such as age-related macular degeneration and diabetic macular edema is projected to rise dramatically in the coming decades with an aging population and the increasing prevalence of diabetes.
The availability of anti-vascular endothelial growth factor (VEGF) therapies has significantly improved outcomes for patients with retinal disease for over a decade. However, the need for frequent intravitreal injections required to obtain the best possible patient outcomes with anti-VEGF therapies has added to the patient burden associated with retinal disease management. This also led many clinicians and patients to opt for as-needed dosing intervals guided by optical coherence tomography results, which may be more expedient for patients but has also been associated with worsening of retinal disease and vision loss. Thus, an unmet need persists for more efficacious therapies with increased duration of response to minimize the number of injections required for the many patients with retinal disease. There are newly available therapeutic options, such as the port delivery system with ranibizumab and the dual anti-VEGF, anti-Ang-2 binding faricimab; along with several emerging, novel therapies including sustained-release anti-VEGF formulations, combination anti-VEGFs, and gene therapy.
The program, “Updates in Retinal Disease Care: Keeping an Eye on Emerging Anti-VEGF Therapies and the Potential for Improved Patient Outcomes” will deliver much-needed, up-to-date information on evidence-based strategies for dosing available anti-VEGF therapies and for integrating newly approved therapies into practice; with reviews of current clinical data from emerging retinal disease therapies.
This intended audience for this educational initiative is ophthalmologists and clinicians who manage patients with retinal disease.
Jointly provided by the Potomac Center for Medical Education and Rockpointe
Supported by an educational grant from Genentech, a member of the Roche Group.
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
A Breath of Fresh Air: New Treatment Strategies for Chronic Rhinosinusitis with Nasal Polyps
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.